| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Annovis Bio, Inc.$1.67
+0.01 (+0.66%)
D 29Pipeline Score Overvalued Pharma · Clinical
Market Cap
64.44 M
EPS
-1.72
P/E Ratio
-1.08 $
Value Trade
1.27 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
16.72 M
Operating CF
-9.01 M
Total Assets
16.24 M
Total Liabilities
13.12 M
Equity
3.13 M
D/E Ratio
12,345
9.85 %
Week
17.99 %
1 Month
-5.51 %
3 Month
-42.97 %
6 Month
-96.58 %
5 Year
-66.37 %
All Time
Cash Data
Cash Position
14.22 M
Monthly Burn
3.00 M
Runway
2.3 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
499.66 K
52 Week Range
1.54 - 5.50
% held by Insiders
11.12 %
% held by Institutions
13.28 %
Enterprise Value
50.22 M
Total Shares
34.66 M
Short %
18.01 %
Float Shares
30.26 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Annovis Bio, Inc.
287Total events
9Upcoming
50Tier-1 (high impact)
2019 – 2027Coverage
Upcoming catalysts 2
TBD
T1NDA Submission
Subscribe to view catalyst details
TBD
T2Enrollment Complete
Subscribe to view catalyst details
Event history 2
TBD
◆Management ChangeCorporate
Subscribe to view catalyst details
TBD
●Runway Guidance UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-07-31 | (ANVS402) | Phase 2/3 data readout | Phase 2/3 | — | – | – | – |
2024-07-31 | (ANVS402) | Phase 2/3 data readout | Phase 2/3 | — | – | – | – |
2024-07-31 | (ANVS402) | Phase 2/3 data readout | Phase 2/3 | — | – | – | – |
Drug Pipeline Intelligence
D29
Pipeline Score $11M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 36%
Micro Cap (rank 585 of 913)
Percentile RankAnnovis Bio, Inc. faces pipeline headwinds (29/100), with $527M risk-adjusted pipeline value, led by buntanetap/posiphen in Early Alzheimers Disease (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| buntanetap/posiphen Small molecule | Early Alzheimers Disease | Phase 3 | NCT06709014 | 44% | $397M | ACTIVE NOT_RECRUITING | 760 | FAST | B (76) | Jun 1, 2028 | LOW_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
buntanetap | Alzheimer's disease | Phase 2/3 | 2026-04-28 | 351 patients; 12 weeks; statistically significant, dose-dependent improvements in cognition; 30 mg dose demonstrated a consistent treatment effect across all analyzed patient groups Read More | Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio Read More | |
buntanetap | Alzheimer's disease | Phase 2/3 | 2026-04-28 | 351 patients; 12 weeks; statistically significant, dose-dependent improvements in cognition; 30 mg dose demonstrated a consistent treatment effect across all analyzed patient groups Read More | Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio Read More | |
buntanetap | Alzheimer's disease | Phase 2/3 | 2026-04-28 | 351 patients; 12 weeks; statistically significant, dose-dependent improvements in cognition; 30 mg dose demonstrated a consistent treatment effect across all analyzed patient groups Read More | Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANVS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ANVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ANVSAnnovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
Annovis Bio has promoted Cheng Fang, Ph.D., to Chief Scientific Officer, a role crucial as the company approaches significant milestones in its Phase 3 clinical trials for the drug candidate, buntanetap. Dr. Fang, who has been with Annovis since 2021, will oversee scientific strategy and research operations for Alzheimer's and Parkinson's disease programs. Her leadership is expected to enhance the company's efforts in clinical development and regulatory interactions.
Read more →ANVS▼ -7.6%on this news
Annovis Bio Regains NYSE Listing Compliance
Annovis Bio has successfully regained compliance with NYSE listing standards after addressing previous non-compliance issues related to market capitalization and stockholders' equity. The company executed corrective actions and provided regular updates to the NYSE, leading to confirmation of compliance ahead of the 18-month deadline. Annovis continues to focus on its clinical programs for Alzheimer's and Parkinson's diseases.
Read more →ANVS▲ +5.2%on this newsshared move
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
Annovis Bio, Inc. has announced a public offering of 7,895,000 shares of common stock and accompanying warrants, aiming to raise approximately $15 million. The funds will be used for the clinical development of its investigational therapy, buntanetap, for Alzheimer's and Parkinson's diseases. The offering is expected to close on May 21, 2026, pending customary conditions.
Read more →ANVS▼ -5.4%on this newsshared move
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
Annovis Bio, Inc. has announced a proposed public offering of common stock and accompanying warrants to support the clinical development of its lead drug, buntanetap, for neurodegenerative diseases. The offering is subject to market conditions, and details will be filed with the SEC. The net proceeds will be used for continued Phase 3 studies and general corporate purposes.
Read more →ANVSAnnovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
Annovis Bio, Inc. reported significant progress in its clinical trials for Alzheimer's and Parkinson's diseases. The Phase 3 trial for Alzheimer's is nearing full enrollment, with a positive safety review. The company anticipates submitting a New Drug Application for its drug, buntanetap, in early 2027. However, financial results show increased losses and reduced cash reserves.
Read more →ANVS▼ -5.8%on this news
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
Annovis Bio's CEO, Maria Maccecchini, will present at Fierce Biotech Week 2026, discussing the multi-protein model of Alzheimer's disease. The presentation will highlight the importance of addressing multiple neurotoxic proteins in disease progression, contrasting with the traditional single-protein focus. Annovis's lead drug, buntanetap, is currently in a pivotal Phase 3 trial.
Read more →ANVSAnnovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
Annovis Bio published promising results from its Phase 2/3 trial of buntanetap for early Alzheimer's disease. The study demonstrated significant cognitive improvements and a favorable safety profile, including in ApoE4 carriers. Biomarker analyses suggest potential disease-modifying effects. The company is advancing to a pivotal Phase 3 trial, with 80% patient enrollment completed.
Read more →ANVSAnnovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Annovis Bio, Inc. has successfully closed a $10 million public offering, extending its cash runway through Q2 2027. This funding will support the Phase 3 trial of its Alzheimer's treatment, buntanetap, which is 75% enrolled. The company anticipates a 6-month data readout in Q1 2027 and has begun preparations for a New Drug Application submission to the FDA. Additionally, an open-label study in Parkinson's disease is underway.
Read more →ANVS▼ -29.6%on this newsshared move
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
Annovis Bio, Inc. has announced a $10 million underwritten offering of common stock and accompanying warrants. The offering consists of 5,263,156 shares priced at $1.90 each, with warrants exercisable at $2.50. Proceeds will support the clinical development of its lead therapy, buntanetap, for Alzheimer's disease. The offering is expected to close around April 10, 2026.
Read more →ANVS▲ +7.5%on this news
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Annovis Bio has secured a U.S. patent for its investigational therapy, buntanetap, aimed at preventing and treating neurological injuries from brain infections. This patent, which extends through 2044, highlights the drug's potential in addressing neurodegenerative diseases like Alzheimer's and Parkinson's. Buntanetap works by reducing the overproduction of neurotoxic proteins triggered by infections, offering a new avenue for treatment.
Read more →ANVS▲ +10.9%on this newsshared move
Annovis Publishes Historical Review of Buntanetap in The Scientist
Annovis Bio, Inc. has published a historical review of its lead drug candidate, buntanetap, in The Scientist. The article outlines the drug's development journey from its origins to its current Phase 3 clinical trials for Alzheimer's and Parkinson's diseases. It emphasizes the scientific rigor and corporate evolution involved in the drug's refinement, showcasing Annovis' commitment to transparency and education.
Read more →ANVS▲ +8.1%on this news
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
Annovis Bio, Inc. announced a partnership with NeuroRPM to implement an AI-powered platform for collecting movement data in an ongoing Parkinson's disease study. This collaboration aims to enhance patient symptom monitoring and data collection for the study, referred to as ANVS-25002, which is currently enrolling participants at 25 sites in the U.S. The AI technology will allow real-time tracking of primary symptoms of Parkinson's disease, offering a digital biomarker to assess treatment responses effectively. The study aims to enroll 500 patients and will also utilize advanced biomarker testing methods.
Read more →ANVS▲ +12.3%on this newsshared move
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Annovis Bio, Inc. reported significant advancements in its clinical development for neurodegenerative diseases, including the initiation of a pivotal Phase 3 trial for Alzheimer's disease and an open-label extension study for Parkinson's disease. The company revealed promising biomarker data suggesting the potential of its investigational drug, buntanetap, to modify disease progression. Financial results showed a net loss but improved cash reserves, allowing operations to continue into mid-2026.
Read more →ANVSAnnovis Announces Two Presentations at the AD/PD™ 2026 International Conference
Annovis Bio, Inc. announced two presentations at the AD/PD™ 2026 International Conference, focusing on its investigational therapy, buntanetap, for neurodegenerative diseases. The presentations will cover clinical data on buntanetap's effects in Parkinson's disease and updates on the ongoing Phase 3 trial for Alzheimer's disease. The conference will take place in Copenhagen from March 17-21, 2026.
Read more →ANVSAnnovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
Annovis Bio has received a positive recommendation from an independent Data and Safety Monitoring Board (DSMB) to continue its pivotal Phase 3 trial of buntanetap for Alzheimer's disease. The DSMB found no safety concerns in the 6-month data, allowing the trial to proceed without changes. The trial is currently 40% complete, with key efficacy readouts expected in early 2027 and 2028.
Read more →ANVSAnnovis Announces Open-Label Extension Study for Parkinson's Disease Patients
Annovis Bio, Inc. announced it will start an Open-Label Extension study in January 2026 to evaluate the long-term safety and efficacy of its drug buntanetap for Parkinson's disease patients. The study aims to enroll 500 patients and will gather data over a 36-month treatment period. Participants will be monitored for continued improvements and biomarker data will be collected to further assess buntenetap's potential as a disease-modifying treatment. This study is essential for advancing toward a New Drug Application submission.
Read more →ANVSAnnovis to Host Corporate Update Webinar on January 28, 2026
Annovis Bio, Inc. (NYSE: ANVS) has announced a corporate update webinar scheduled for January 28, 2026, featuring CEO Maria Maccecchini, Ph.D. The session aims to provide an overview of the company's recent progress, ongoing clinical programs, and future strategic directions. Shareholders and other interested parties are invited to participate, and they can submit questions in advance. The company has noted strong momentum driven by clinical advancements and anticipates sharing key updates during the session.
Read more →ANVS▲ +5.4%on this news
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
Annovis Bio, Inc. announced that it will present at the 2025 Annual Meeting of the Parkinson Study Group in San Diego, California. This presentation will include recent Phase 3 data showing the efficacy of their drug buntanetap, particularly in patients with amyloid co-pathology. Findings indicate that buntanetap not only counteracts cognitive decline but also reduces tau biomarkers in Parkinson's disease patients. Additionally, a cross-study comparison will be unveiled, underscoring the cognitive gains in patients treated with the drug, establishing its potential as a significant therapeutic option.
Read more →ANVS▲ +7.9%on this news· ran to +35% by day 3
Annovis Announces Two Presentations at the CTAD 2025 Conference
Annovis Bio, Inc. announced two presentations at the CTAD 2025 Conference focusing on Alzheimer’s and Parkinson’s disease. The presentations will emphasize recent biomarker data regarding their drug, buntanetap, which may provide disease-modifying benefits. The CEO articulated optimism about these results and their implications for future treatments. The conference will take place from December 1-4, 2025, in San Diego, California.
Read more →ANVS▲ +11.2%on this news· ran to +25% by day 3
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
Annovis Bio announced a scheduled Type C meeting with the FDA in January 2026 to discuss its Parkinson's disease dementia (PDD) program. The company emphasized the significance of this opportunity to address a largely underserved patient population. Additionally, Annovis reiterated that its Phase 3 Alzheimer's disease clinical trial is progressing well with full regulatory alignment on its parameters. The ongoing studies highlight the therapeutic potential of buntanetap in addressing cognitive decline associated with neurodegenerative diseases.
Read more →ANVS▲ +29.5%on this news· ran to +66% by day 3shared move
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
Annovis Bio has reported promising new biomarker data regarding its drug, buntanetap, in Parkinson’s patients, particularly those with Alzheimer’s co-pathology. The Phase 3 study showed that patients receiving treatment experienced significant cognitive improvements, especially those with mild dementia and co-existing Alzheimer’s pathology. Buntanetap demonstrated disease-modifying effects by reducing key neurodegenerative biomarkers, emphasizing its potential in addressing cognitive decline. The findings will be presented at the upcoming Clinical Trials on Alzheimer's Disease conference in December 2025.
Read more →ANVS▲ +15.2%on this news· ran to +44% by day 3shared move
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
Annovis Bio, Inc. reported significant advancements in its clinical studies and corporate structure during the third quarter of 2025. The company's pivotal Phase 3 Alzheimer's study has fully activated all clinical sites, with increasing enrollment. Additionally, promising biomarker findings from a Phase 2/3 study suggest potential disease-modifying effects of their drug, buntanetap. The company has also enhanced its leadership team by appointing a new CFO.
Read more →ANVSAnnovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
Annovis Bio has successfully activated all 84 clinical sites for its Phase 3 Alzheimer's study, with the first group of participants completing the 6-month treatment milestone. The trial is currently 25% complete and is expected to deliver symptomatic data in the second half of 2026. The study aims to enroll 760 patients with early Alzheimer's disease.
Read more →ANVSAnnovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
Annovis Bio, Inc. has announced a registered direct offering of common stock, aiming to raise approximately $3.4 million. The offering involves the sale of 1,670,732 shares at a price of $2.05 per share, reflecting the market closing price. The proceeds will be utilized for working capital and general corporate purposes, with the closing expected around October 28, 2025.
Read more →ANVS▲ +12.2%on this news
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
Annovis Bio, Inc. has successfully closed a registered direct offering, raising approximately $6 million by selling 4,000,000 shares of common stock at $1.50 each. The proceeds will be used for working capital and general corporate purposes. The offering was facilitated by H.C. Wainwright & Co., and the securities were sold under a previously filed registration statement with the SEC.
Read more →ANVS▼ -22.7%on this newsshared move
Annovis Announces $6 Million Registered Direct Offering of Common Stock MALVERN, Pa.
Annovis Bio, Inc. has announced a registered direct offering of common stock, aiming to raise approximately $6 million by selling 4 million shares at $1.50 each. This offering is part of the company's strategy to secure working capital and support its clinical initiatives for neurodegenerative diseases such as Alzheimer's and Parkinson's. The anticipated closing date for the offering is around October 13, 2025, pending customary conditions. H.C. Wainwright & Co. will serve as the exclusive placement agent for the transaction.
Read more →ANVSAnnovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment
Annovis Bio announced promising biomarker data for buntanetap in Alzheimer's patients, indicating its potential to modify the disease rather than just alleviate symptoms. The Phase 2/3 study revealed significant reductions in inflammation and improvements in neuronal health. These findings support the ongoing pivotal Phase 3 trial aimed at further assessing the drug's efficacy.
Read more →ANVSAnnovis Appoints Mark Guerin as Chief Financial Officer
Annovis Bio has appointed Mark Guerin as Chief Financial Officer to guide the company during a crucial phase of development for its drug, buntanetap, which is in late-stage trials for neurodegenerative diseases. Guerin has a strong background in financial operations within biopharma, having held key positions in several companies. His expertise is expected to support Annovis' mission to deliver effective therapies for conditions like Alzheimer's and Parkinson's diseases.
Read more →ANVSAnnovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap
Annovis Bio has published a peer-reviewed article detailing the pharmacokinetics of a new crystal form of buntanetap. This new dihydrate form demonstrates greater stability and maintains the pharmacokinetic profile of the original form. The findings support its use in ongoing Phase 3 clinical trials for Alzheimer's disease, with key readouts expected in 2026 and 2027.
Read more →ANVSAnnovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Annovis Bio, Inc. announced that its CEO, Dr. Maria Maccecchini, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The conference will take place at the Lotte New York Palace Hotel. Annovis is focused on developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's.
Read more →ANVSAnnovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results Malvern, Pa.
Annovis Bio, Inc. (ANVS) announced updates and its financial results for Q2 2025, highlighting the ongoing enrollment for its pivotal Phase 3 trial in early Alzheimer's disease. The trial has secured 76 clinical sites across the U.S. and has screened over 400 patients. The company reported a net loss of $0.32 per share, although it improved its cash reserves significantly since the previous year. Additionally, key scientific presentations were made at AAIC 2025, showcasing the progress of Annovis' lead drug candidate, buntanetap.
Read more →ANVSAnnovis Completes Full Patent Transfer to Crystal Buntanetap
Annovis Bio, Inc. has completed the full patent transfer for its drug candidate, buntanetap, securing comprehensive intellectual property protection that extends to 2046. This includes protections for both the new crystalline form and the original semi-crystalline form, covering 13 patent families internationally. The company has characterized the new crystalline form with improved stability and demonstrated bioequivalence with the original form in studies. Additionally, the FDA approved the new crystalline form for use in a Phase 3 clinical trial targeting early Alzheimer's disease, enhancing its market position and potential applications.
Read more →ANVS▼ -5.2%on this news
Annovis to Attend the AAIC 2025 with Four Poster Presentations
Annovis Bio, Inc. has announced its participation at the Alzheimer's Association International Conference (AAIC) 2025, scheduled for July 27-31 in Toronto, Canada. The company will present four scientific posters that focus on their lead drug candidate, buntanetap, including its efficacy and safety in treating early Alzheimer's patients. This event represents an important opportunity for Annovis to share research findings with the global community dedicated to dementia science. The conference will bring together researchers and professionals to discuss and advance the treatment of neurodegenerative diseases.
Read more →ANVSAnnovis Announces NYSE Acceptance of Plan to Regain Listing Compliance Malvern, Pa.
Annovis Bio, Inc. announced the acceptance of its plan by the New York Stock Exchange to regain compliance with minimum listing standards. The NYSE granted the company an 18-month period, during which it must provide quarterly updates on its progress. This plan reflects the company's commitment to maintaining its listing while continuing its focus on therapies for neurodegenerative diseases. However, there are inherent risks associated with achieving compliance within the specified timeframe.
Read more →ANVS▼ -5.9%on this news
Annovis to Host Webinar and Live Q&A on June 24, 2025
Annovis Bio, Inc. announced it will host a live webcast on June 24, 2025, where CEO Maria Maccecchini will provide updates on clinical trials, including a pivotal Phase 3 trial for early Alzheimer's disease. The webcast aims to engage shareholders and the public, allowing participants to ask questions directly. The company also emphasizes its commitment to developing therapies for neurodegenerative diseases, including feedback from the FDA on Parkinson's disease program.
Read more →ANVS▲ +9.7%on this news
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results Malvern, Pa.
Annovis Bio Inc. announced its Q1 2025 financial results and corporate updates, focusing on the initiation of a pivotal Phase 3 clinical trial for Alzheimer's disease. The trial aims to evaluate the drug buntanetap's benefits over 6 and 18 months, with patient enrollment underway. Despite strong advancements in its clinical programs, the company reported a net loss of $5.54 million for the quarter, although cash reserves increased significantly compared to the previous year. Annovis emphasizes its commitment to developing transformative therapies for neurodegenerative diseases.
Read more →ANVS▼ -5.2%on this news
Annovis Bio Appoints Hui Liu as Director of Biostatistics
Annovis Bio Inc. has appointed Hui Liu as Director of Biostatistics amid the advancement of its pivotal Phase 3 clinical trial for Alzheimer's disease. Liu's extensive experience in clinical trial design and analysis will contribute to the integrity of data and regulatory submissions. Her role is expected to strengthen the company’s commitment to scientific excellence and support their ongoing efforts in developing therapies for neurodegenerative disorders. The announcement reflects a proactive approach in aligning expert talent with the company's strategic goals.
Read more →ANVSAnnovis Bio, Inc.
Annovis Bio, Inc. (NYSE: ANVS) announced it received a notice from the NYSE indicating non-compliance with continued listing standards due to low market capitalization and stockholders' equity. The notice does not disrupt the company's operations and the company plans to submit a remediation plan within 45 days. The NYSE will review the plan and determine whether it meets compliance standards within 18 months. In the interim, the company's stock will trade under the symbol 'ANVS.BC'.
Read more →ANVSAnnovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
Annovis Bio, Inc. has received a notice from the New York Stock Exchange indicating non-compliance with listing standards due to its market capitalization falling below $50 million. The company is required to submit a plan within 45 days to regain compliance, and has 18 months to address the issue. While this notice does not immediately affect trading, it puts the company at risk of delisting if it fails to comply with the NYSE's requirements.
Read more →ANVS▲ +6.5%on this newsshared move
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
Annovis Bio Inc. will participate in the AD/PD™ 2025 conference in Vienna from April 1-5, where it will present new data from its late-stage studies for Alzheimer's and Parkinson's diseases. The company will showcase findings on its drug, buntanetap, focusing on its effects on cognitive responses in Parkinson's patients and benefits for APOE4 carriers in Alzheimer's treatment. The participation underscores Annovis's commitment to advancing treatment for these neurodegenerative disorders amidst growing interest in the field.
Read more →ANVSAnnovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results Malvern, Pa.
Annovis Bio Inc. announced progress in its clinical trials for its drug candidate, buntanetap, addressing neurodegenerative diseases like Alzheimer's and Parkinson's. The company completed pivotal Phase 2/3 trials for Alzheimer's and Phase 3 trials for Parkinson's, showing promising results that led to FDA clearance for a new trial. Financial results indicated a net loss reduction compared to the previous year, and the company continues to expand its patent portfolio and professional team. The CEO expressed satisfaction with the company's achievements and ongoing momentum as they head into 2025.
Read more →ANVSAnnovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
Annovis Bio Inc. (NYSE: ANVS) will participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit from March 18-20 in Boston, MA. CEO Maria Maccecchini plans to present findings from clinical trials, emphasizing a holistic approach to treating neurodegenerative diseases like Parkinson's. Annovis aims to address multiple neurotoxic proteins, moving beyond traditional narrow therapeutic strategies. The summit will facilitate discussions on future advancements in treatments for these complex conditions.
Read more →ANVS▼ -6.9%on this news· ran to -21% by day 3
Annovis to Host Patients’ Live Forum on February 27, 2025
Annovis Bio, Inc. will host a Patients’ Forum on February 27, 2025, featuring CEO Maria Maccecchini. The event aims to address patient inquiries regarding clinical trials for Alzheimer's and Parkinson's diseases, alongside updates on ongoing studies. Attendees will have the opportunity to engage in a Q&A session and submit questions in advance, demonstrating Annovis' focus on patient involvement and communication.
Read more →ANVSAnnovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Annovis Bio Inc. announced that its CEO, Maria Maccecchini, will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The presentation will focus on recent advancements, particularly the pivotal Phase 3 trial for Alzheimer's disease and the strategic direction toward a New Drug Application for the company's drug, buntanetap. The event aims to engage industry leaders and investors, providing insights into current trends and potential investment opportunities in healthcare.
Read more →ANVSAnnovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease MALVERN, Pa.
Annovis Bio Inc. has announced the enrollment of the first two patients in a pivotal Phase 3 study for its drug candidate, buntanetap, targeting early Alzheimer's disease. The study is designed to evaluate the drug's efficacy and safety over an 18-month period, with assessments for both symptomatic relief and potential disease modification. The trial is made possible through a recent public offering, which raised $21 million, ensuring funding for its initial six-month phase. Previous trials have shown promising results, positioning the company favorably to meet the unmet medical needs of Alzheimer's patients.
Read more →ANVSAnnovis Bio, Inc. Announces Closing of $21 Million Public Offering
Annovis Bio, Inc. announced the successful closing of its public offering, raising $21 million by selling 5,250,000 shares and warrants at a price of $4.00 each. The proceeds will primarily be used for continuing clinical trials of its lead compound, Buntanetap, in a Phase 3 study aimed at treating Alzheimer's disease. The warrants have an exercise price of $5.00 and are immediately exercisable. Despite the positive fundraising outcome, the company faces various risks related to clinical trial execution and potential drug effectiveness.
Read more →ANVS▼ -33.5%on this newsshared move
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
Annovis Bio, Inc. announced a public offering of 5,250,000 shares at a price of $4.00 per share, with gross proceeds expected to reach $21 million. The funds will primarily be used for working capital and advancing the clinical development of its lead compound, Buntanetap. The offering is set to close on February 4, 2025, pending customary closing conditions. The company is utilizing a shelf registration statement for the offering, reflecting its compliance with SEC regulations.
Read more →ANVSAnnovis Bio, Inc. Announces Proposed Public Offering MALVERN, PA
Annovis Bio, Inc. announced a proposed public offering of common stock and warrants to raise funds for clinical development. The offering will be managed by ThinkEquity, with an option for additional shares to cover over-allotments. The proceeds are expected to support the company's ongoing research and development efforts, particularly for its lead compound, Buntanetap. However, the company acknowledges that the proposed offering is contingent upon market conditions, and there are risks associated with patient enrollment and clinical trial outcomes.
Read more →ANVSAnnovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
Annovis Bio Inc. has been granted a U.S. patent for its drug, buntanetap, aimed at treating and preventing acute brain or nerve injuries. The patent, issued on January 2, 2025, enhances the company's protection for its innovative therapies against neurodegenerative diseases. Buntanetap's potential applications include conditions such as stroke and traumatic brain injury, showcasing its ability to reduce neurotoxicity. This patent complements similar approvals already obtained in Europe, Japan, and worldwide, emphasizing the company's expanding intellectual property portfolio.
Read more →ANVS▲ +6.3%on this news
Annovis to Host Year-End Investor Webcast on December 11, 2024
Annovis Bio, Inc. has announced a live investor webcast scheduled for December 11, 2024, led by CEO Dr. Maria Maccecchini. The webcast will provide updates on the company's achievements, ongoing clinical programs for neurodegenerative diseases, and financial strategies. Key discussions will include insights into Phase 3 studies for Parkinson's and Alzheimer's, regulatory milestones with the FDA, and plans for the coming year. Participants can submit questions in advance for the Q&A session following the presentation.
Read more →ANVSAnnovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
Annovis Bio Inc. (ANVS) has been invited to present at the National Institute on Aging workshop focused on Dementia with Lewy Bodies. The workshop aims to address significant gaps in research related to this condition and will take place on November 12-13, 2024. The company's CEO, Maria Maccecchini, will discuss the potential dual benefits of Buntanetap for both Alzheimer's and Parkinson's patients during her presentation. This opportunity underscores Annovis's commitment to pioneering treatment options for neurodegenerative diseases.
Read more →ANVS▼ -6.2%on this newsshared move
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update MALVERN, Pa.
Annovis Bio announced its third quarter financial results and highlighted significant milestones, including FDA approval to start Phase 3 studies for early Alzheimer's disease. The company also reported advancements in its intellectual property portfolio, filing patents for new combinations of Buntanetap. However, the announcement acknowledged certain risks and uncertainties, such as patient enrollment challenges and the drug's effectiveness. Overall, Annovis remains dedicated to addressing neurodegenerative diseases, indicating a proactive approach towards clinical development.
Read more →ANVSAnnovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
Annovis Bio Inc. has appointed Matthew Peterson, Ph.D., as Senior Clinical Scientist, enhancing the team's expertise in clinical research. Dr. Peterson will oversee the quality and rigor of the company’s clinical trials as they near the initiation of pivotal Phase 3 studies for their therapy, Buntanetap. With significant experience in the life sciences and a history of improving patient outcomes, Dr. Peterson's role is seen as critical during this important phase for the company. His prior work includes leading significant studies in various medical conditions, including those affecting veterans.
Read more →ANVSAnnovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
Annovis Bio Inc. (ANVS) is set to present two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled for October 29 to November 1, 2024, in Madrid, Spain. The presentations will focus on the efficacy of Buntanetap in early Alzheimer’s disease and its potential benefits in reducing neurotoxic proteins and enhancing neuronal functions. This engagement with leading figures in the Alzheimer’s research community underscores the company's dedication to advancing treatments for neurodegenerative disorders.
Read more →ANVS▲ +6.3%on this news· ran to +23% by day 3
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs MALVERN, Pa.
Annovis Bio Inc. received FDA clearance to initiate pivotal Phase 3 studies for its Alzheimer's drug, buntanetap. Following a successful End-of-Phase 2 meeting, the company will conduct two trials to assess the drug's symptomatic effects and potential for disease modification in early Alzheimer's patients. The development aligns with the company's goal of submitting New Drug Applications in a timely manner, potentially within a year of the studies' initiation. The FDA has raised no concerns regarding the safety data of buntanetap.
Read more →ANVSAnnovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
Annovis Bio Inc. (NYSE: ANVS) is advancing the development of innovative treatments for neurodegenerative diseases, specifically Alzheimer’s and Parkinson’s diseases. The company's primary drug candidate, buntanetap, has shown efficacy in clinical trials, including a notable phase 2/3 trial for early Alzheimer’s with favorable results. Annovis aims to improve brain health and cognition by targeting neurotoxic proteins, enhancing the quality of life for patients. The emphasis on a combination therapy approach may signify a transformative step in Alzheimer's treatment.
Read more →ANVS▲ +5.4%on this newsshared move
Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
Annovis Bio Inc. has recently announced its involvement in an editorial discussing innovative approaches in Alzheimer's disease treatment. The article highlights the limitations of existing FDA-approved drugs on cognitive function and emphasizes the potential of combinations with GLP-1 drugs. Annovis's research utilizing its lead drug, buntanetap, has yielded promising preliminary results. The company aims to address neurodegenerative conditions such as Alzheimer's and Parkinson's by targeting neurotoxic proteins to enhance brain function.
Read more →ANVSAnnovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra MALVERN, Pa.
Annovis Bio Inc. has announced the filing of three new patents for combination therapies involving its lead compound, buntanetap, along with FDA-approved drugs Trulicity and Viagra. These combinations have demonstrated a strong potential to enhance cognitive function in preclinical studies, with results indicating improvements beyond normal levels in Alzheimer's mouse models. The company aims to advance these promising combinations into Phase 3 human trials, further broadening its pipeline in the treatment of neurodegenerative disorders like Alzheimer's and Parkinson's diseases.
Read more →ANVS▼ -6.8%on this news
Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
Annovis Bio Inc. (NYSE: ANVS) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. Dr. Maria L. Maccecchini, the company’s CEO, will present on September 10, providing an overview of Annovis’ advancements in neurodegenerative disease therapies. She will also participate in a panel discussing innovative non-amyloid approaches to Alzheimer's Disease, alongside representatives from other companies. Attendees are encouraged to check the agenda for the latest updates.
Read more →ANVS▲ +14%on this news
Annovis Bio Reports Second Quarter Financial Results and Provides Business Update MALVERN, Pa.
Annovis Bio reported its financial results for the second quarter of 2024, highlighting progress in its clinical studies for Alzheimer's and Parkinson's diseases. The company announced encouraging data from Phase 2/3 studies for its drug, buntanetap, and introduced a new crystalline form of the drug, enhancing its intellectual property. Despite these positive developments, the company acknowledged certain risks such as patient enrollment challenges and uncertainties regarding the drug's effectiveness in clinical trials.
Read more →ANVSAnnovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist MALVERN, Pa.
Annovis Bio Inc. has reported promising preclinical data indicating that its lead compound, buntanetap, can synergistically enhance cognition when combined with the GLP-1 agonist dulaglutide in a mouse model for Alzheimer's disease. The combination not only restored cognitive function but surpassed recovery levels of healthy controls. This finding potentially lays the groundwork for more effective combination therapies for neurodegenerative diseases, attracting attention in ongoing Alzheimer's research.
Read more →ANVSAnnovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
Annovis Bio has announced the issuance of a U.S. patent for its lead drug candidate, buntanetap, for the treatment of acute traumatic brain injuries (TBI). This patent enhances the company's existing portfolio, which includes treatments for Alzheimer’s and Parkinson’s diseases. Buntanetap targets neurodegeneration by inhibiting neurotoxic proteins, potentially reversing degenerative processes. The CEO expressed excitement over this milestone and emphasized the drug's importance in tackling brain trauma, a significant issue in the U.S.
Read more →ANVSAnnovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap MALVERN, Pa.
Annovis Bio has received FDA approval to transition to a new solid form of its drug, buntanetap, which aims to treat neurodegenerative disorders like Alzheimer's and Parkinson's disease. The approval allows the company to conduct comparative studies between the old and new forms to enhance bioavailability. This development is part of Annovis's broader strategy to target neurotoxicity and improve patient outcomes in neurodegenerative diseases.
Read more →ANVS▼ -5.8%on this news· ran to -22% by day 1
Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
Annovis Bio has announced the addition of four new executives to strengthen its leadership team. Mark White joins as Chief Business Officer, bringing significant marketing and business development experience, while Dr. Alexander Morin takes on the role of Director of Strategic Communications. Hilda Maibach will serve as Senior Vice President of Statistics, offering over 30 years of experience in clinical studies, and Blake Jensen is appointed Head of Quality, contributing his extensive industry experience. The company aims to use this strengthened leadership to progress its drug, buntanetap, towards market readiness for Alzheimer’s and Parkinson’s diseases.
Read more →ANVS▲ +76.1%on this news· ran to +193% by day 3
Annovis Bio Announces New Data from Phase III Parkinson's Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap Buntanetap showed dose-depen
Annovis Bio has announced promising new data from its Phase III study on Buntanetap, highlighting significant improvements in both motor and cognitive functions among early-stage Parkinson's disease patients. The study demonstrated statistically significant enhancements in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), particularly for those with a diagnosis of more than three years and in patients with Postural Instability and Gait Difficulties. The company's commitment to advancing Buntanetap further aims to establish its symptom-relieving and potential disease-modifying effects in neurodegenerative disorders.
Read more →ANVSAnnovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
Annovis Bio Inc. has filed a provisional patent for a new manufacturing process of a crystalline form of its drug, buntanetap, which targets neurodegenerative disorders such as Alzheimer's and Parkinson's Disease. This patent covers all aspects of production, ensuring control and protection of intellectual property. The new process is expected to yield a purer product and avoid harmful reagents. Annovis plans to submit a New Drug Application (NDA) based on this new crystal form, demonstrating its commitment to advancing treatment options for patients with neurodegenerative conditions.
Read more →ANVSAnnovis Bio Files Patent for New Composition of Matter for Buntanetap
Annovis Bio Inc. has filed a new composition of matter patent for novel crystalline forms of its drug buntanetap, aimed at treating neurodegenerative disorders like Alzheimer's and Parkinson's diseases. This patent enhances the drug's properties and secures protection for its uses over a 20-year term. The most stable form of buntanetap is now set for animal studies, and the next steps will include submitting data to the FDA. This development marks a significant milestone for Annovis as it seeks to move closer to filing an NDA for the drug.
Read more →ANVS▼ -8.7%on this newsshared move
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
Annovis Bio Inc. (NYSE: ANVS) has announced an investor webcast scheduled for July 2, 2024, to discuss developments regarding its lead drug candidate, Buntanetap, targeted at treating neurodegenerative disorders such as Parkinson's Disease. During the call, the company will cover recent advancements, as well as its strategic plans for upcoming clinical trials. Buntanetap aims to inhibit neurotoxic proteins to help reverse degeneration in affected patients. However, the company has acknowledged potential risks that may impact their projected outcomes in clinical testing.
Read more →ANVSAnnovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference 2024
Annovis Bio Inc. has been chosen to present its latest findings on Alzheimer's treatment at the Alzheimer’s Association International Conference 2024, scheduled for July 28 to August 1 in Philadelphia. The presentation will highlight data from their Phase 2/3 study of Buntanetap, focusing on its efficacy and safety among patients with mild Alzheimer's disease. Senior executives from Annovis, along with prominent figures from Duke University, will discuss the potential of this treatment during a dedicated 45-minute session. This conference serves as a key platform for advancements in dementia research, fostering knowledge exchange among scientists worldwide.
Read more →ANVSAnnovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients Join Our Investor Call for In-Depth Findings Discussion MALVERN, Pa., June,11 2024 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("A
Annovis Bio Inc. announced that its lead drug candidate, Buntanetap, has been found safe and effective in a Phase II/III study involving high-risk Alzheimer's patients. The study indicates significant efficacy in both APOE4 carriers and non-carriers, with no serious adverse events related to the drug. In light of these findings, Annovis is planning to initiate an 18-month Phase III trial for biomarker-positive early Alzheimer's patients. The results represent a promising development in the treatment of neurodegenerative diseases, particularly for a subset of patients at higher risk.
Read more →ANVSAnnovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast MALVERN, Pa.
Annovis Bio Inc. is set to host an investor webcast to discuss its recent progress and future strategies regarding its lead drug candidate, Buntanetap. This innovative therapy aims to tackle neurodegenerative diseases such as Alzheimer's and Parkinson's by inhibiting the formation of neurotoxic proteins. The webcast will provide insights into the company's plans and ongoing developments. Registration for the event is now open to investors and interested parties.
Read more →ANVS▼ -5.9%on this news· ran to -17% by day 3
Annovis Announces New Publication in a Peer-Reviewed Journal MALVERN, Pa .
Annovis Bio, Inc. announced a new publication detailing a systematic comparison of the pharmacokinetic profiles of its drug Posiphen across various species, including humans. This publication, featured in the peer-reviewed journal Biomolecules, provides valuable insights into the drug’s absorption and metabolism. Maria Maccecchini, the company's CEO, emphasized the significance of this work in showcasing the comprehensive data collected from multiple studies. The publication aims to better understand how animal models relate to human responses, thereby informing future clinical implications.
Read more →ANVS▲ +15.5%on this news· ran to +41% by day 1
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results MALVERN, Pa .
Annovis Bio, Inc. has reported positive updates from their clinical trials for neurodegenerative diseases, particularly highlighting cognitive improvements in Alzheimer's patients based on ADAS-Cog 11 scores. The company is winding down two key clinical trials, with expectations to release topline results for their Parkinson's disease study in June. Their drug, Buntanetap, is aimed at addressing multiple neurotoxic proteins, indicating a promising approach to treatment. However, the company also acknowledges inherent risks in their trial processes and forward-looking statements.
Read more →ANVS▲ +25.1%on this news· ran to +73% by day 3shared move
ANNOVIS ANNOUNCES UNBLINDING OF THE BUNTANETAP PHASE III DATA IN PARKINSON'S DISEASE MALVERN, Pa .
Annovis Bio, Inc. announced the completion of data cleaning for the Phase III study of its drug, buntanetap, in patients with early Parkinson's disease. Though there was a delay in the announcement of topline data, caused by a higher-than-expected number of blank plasma samples, the company has resolved the issues and is preparing to present results in June. The CEO confirmed confidence in the data following the thorough review process, which included checks on sample integrity and measurement methods.
Read more →ANVSAnnovis Bio CEO Maria Maccecchini Issues Letter to Stockholders MALVERN, Pa .
Annovis Bio, Inc. CEO Maria Maccecchini addressed stockholders regarding the company's recent Phase II/III trial results for its Alzheimer's treatment, which faced criticism leading to a decrease in share price. Despite the setback, Maccecchini highlighted the study's contribution to the design of future trials, including patient prescreening and a focus on early-stage Alzheimer's patients. The company remains dedicated to advancing its drug, buntanetap, for both Alzheimer's and Parkinson's diseases, aiming to improve patient outcomes.
Read more →ANVS▼ -59.6%on this news· ran to -70% by day 3
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Annovis Bio announced statistically significant results from its Phase II/III trial of buntanetap for early Alzheimer's disease patients. In the study, patients receiving the treatment showed a mean improvement of 3.3 points in the ADAS-Cog 11 cognitive assessment compared to a mere 0.3 points in the placebo group. Based on these findings, Annovis intends to conduct a pivotal Phase III trial focusing on biomarker-positive early Alzheimer's patients. The safety profile of buntanetap was found to be favorable, with a majority of adverse events being mild to moderate.
Read more →ANVS▼ -6.5%on this news
ANNOVIS BIO PROVIDES CORPORATE UPDATES AND REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Tue, 02 Apr 2024 MALVERN, Pa.
Annovis Bio provided corporate updates alongside its financial results for Q4 and the full year 2023. The company had successful trial completions for its Parkinson's and Alzheimer's studies, surpassing enrollment expectations and reporting promising biomarker results indicating the effectiveness of its drug, buntanetap. However, it also reported substantial financial losses and a decrease in cash reserves, highlighting significant operational costs associated with its clinical trials.
Read more →ANVSAnnovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Annovis Bio, Inc. announced new data supporting the mechanism of action of its oral drug, buntanetap, as a translational inhibitor of amyloid precursor protein in early Alzheimer's Disease patients. This data comes from a Phase 1b study published recently that assessed the pharmacodynamic effects of the drug. While buntanetap showed promise in lowering amyloid beta production and demonstrated safety and tolerability, the statistical significance of the results is limited due to the small number of patients. The findings align with the drug's potential to mitigate neurodegeneration by targeting multiple neurotoxic proteins.
Read more →ANVS▲ +24.4%on this news
ANNOVIS BIO PROVIDES DATA ANNOUNCEMENT UPDATE FOR THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER'S DISEASE MALVERN, Pa .
Annovis Bio, Inc. announced the successful completion of data cleaning for its phase II/III study of buntanetap in Alzheimer's patients. This study involved over 700 patients with 353 enrolled and 327 completing the trial. Annovis expects to release topline efficacy data in April, highlighting potential advancements in treating neurodegeneration. The company focuses on developing therapies that inhibit multiple neurotoxic proteins associated with Alzheimer's and Parkinson's diseases.
Read more →ANVS▲ +10.4%on this news
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
Annovis Bio, Inc. will participate in the AD/PD™ 2024 conference in Lisbon, Portugal, scheduled for March 5-9, 2024. CEO Maria Maccecchini, PhD, will contribute to a panel discussion on alpha-synuclein, LRKK2, and GBA pathologies, which are significant in neurodegenerative diseases. The forum aims to explore new insights into biomarkers and patient staging for Parkinson's disease and related conditions. This marks an important opportunity for Annovis to showcase its research efforts on an international platform.
Read more →ANVSAnnovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Annovis Bio, Inc. announced the completion of the last patient visit in its phase II/III study of buntanetap for mild to moderate Alzheimer's disease. A total of 327 patients successfully concluded the trial, with minimal dropout rates reported. The company is now focused on analyzing the collected data to produce timely results. Buntanetap targets key neurotoxic proteins linked to neurodegeneration, offering potential therapeutic benefits for Alzheimer's patients.
Read more →ANVS▼ -5.5%on this news
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
Annovis Bio has filed a new patent application for the use of its drug, buntanetap, in treating neuropsychiatric conditions. This filing builds on a previous U.S. Provisional Application and includes disorders such as anxiety, ADHD, and schizophrenia. Buntanetap's ability to target multiple neurotoxic proteins has shown promise in improving mental health as demonstrated in preclinical studies. The CEO highlighted this advancement as a significant step towards providing therapeutic solutions for brain-related disorders.
Read more →ANVS▼ -21.9%on this news
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
Annovis Bio has announced a postponement in the release of Phase III study data for its drug, buntanetap, aimed at treating Parkinson's Disease. The delay is attributed to ongoing efforts to ensure data accuracy and reliability. Despite the setback, the company emphasizes its dedication to providing trustworthy results. The Phase III trial has shown promising early enrollment rates and aims to evaluate the drug's efficacy and safety in combination with standard care.
Read more →ANVS▼ -8.8%on this news
Annovis Bio to Participate in the 139th Yale CEO Summit
Annovis Bio, Inc. (NYSE: ANVS) announced that its Founder and CEO, Dr. Maria Maccecchini, will participate in the 139th Yale CEO Summit in New York, scheduled for December 11-12, 2023. This bi-annual event gathers CEOs from major US Fortune 500 companies for discussions on the theme "Re-imagining Your Strategic Mission with Your Current Leadership." Dr. Maccecchini expressed her honor and eagerness to engage with prominent leaders and share ideas during the summit.
Read more →ANVSAnnovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
Annovis Bio, Inc. announced the completion of the Phase III study for its drug candidate, buntanetap, aimed at treating early Parkinson's disease. Conducted across 67 sites in the U.S. and the EU, the trial involved a total of 471 patients who completed the study, with topline results anticipated in January 2024. The study was noted for its rapid patient enrollment and efficient completion, marking a critical step in developing new therapies for neurodegenerative diseases.
Read more →ANVSAnnovis Bio Appoints Andrew Walsh as Vice President Finance
Annovis Bio, Inc. has appointed Andrew Walsh as Vice President of Finance as part of its growth strategy. Walsh, who brings 12 years of experience from various roles, will support the company's ongoing development efforts for its lead candidate, buntanetap, particularly as pivotal clinical trial data for Alzheimer's and Parkinson's diseases is expected in 2024. The company emphasizes its commitment to advancing novel therapies aimed at neurodegenerative diseases.
Read more →ANVS▲ +13.7%on this news· ran to +31% by day 3
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
Annovis Bio has successfully completed full enrollment for its Phase II/III Alzheimer's disease trial of its lead compound, buntanetap, exceeding initial expectations. The trial, which began in March 2023, successfully enrolled 353 patients across 54 sites in the US. Buntanetap aims to address multiple neurotoxic proteins associated with Alzheimer's, potentially offering a more effective treatment option. Interim analysis has shown positive efficacy, and continuation of the trial is recommended, with data expected by March 2024.
Read more →ANVSAnnovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Annovis Bio, Inc. (ANVS) has announced its third quarter financial results alongside a corporate update, highlighting the progress of its clinical studies for Alzheimer's and Parkinson's diseases. The company reported an increase in patient enrollment for its Alzheimer's disease trial and maintained a strong retention rate in its Parkinson's trial. However, financial results showed a net loss, raising concerns over the sustainability of funding for ongoing clinical trials. The positive interim analysis by the Data and Safety Monitoring Board emphasizes the potential efficacy and safety of their lead candidate, Buntanetap, as further results are anticipated in early 2024.
Read more →ANVSAnnovis Bio Announces Launch of Proposed Public Offering BERWYN, PENNSYLVANIA
Annovis Bio, Inc. announced a proposed underwritten public offering of its common stock and accompanying warrants. The offering aims to raise funds for general corporate purposes, including the development of its lead drug candidate, buntanetap, targeting neurodegenerative diseases such as Alzheimer's and Parkinson's. The company emphasizes that the public offering is subject to market conditions and highlights potential risks associated with clinical trial outcomes.
Read more →ANVSANNOVIS BIO RECEIVES POSITIVE RECOMMENDATION TO CONTINUE PHASE 2/3 TRIAL OF BUNTANETAP FOR alzheimer'S DISEASE PATIENTS FROM THE INDEPENDENT DATA AND SAFETY MONITORING BOARD (DSMB) BERWYN, PENNSYLVANIA
Annovis Bio, Inc. has received a positive recommendation from the Data and Safety Monitoring Board (DSMB) to continue its Phase 2/3 trial of buntanetap, targeting mild to moderate Alzheimer's Disease patients. The DSMB's review indicated that the trial could continue as originally designed, validating the company's research direction. The trial has already recruited 281 of the planned 320 patients, and initial findings suggest an improvement in cognition and tolerability. Buntanetap functions by targeting multiple neurotoxic proteins to address neurodegeneration.
Read more →ANVS▲ +9.2%on this news
ANNOVIS BIO ANNOUNCES POSITIVE interim INDEPENDENT analysis For STATISTICAL POWER IN its Alzheimer's study
Annovis Bio announced a positive interim analysis for its Phase 2/3 Alzheimer's study, confirming that the trial has sufficient statistical power to proceed without additional patients. The independent analysis involved data from 107 patients at six weeks, which supports the study's original sample size of 320. The company's CEO noted that while the trial's positive interim results indicate potential efficacy for the drug, safety and efficacy data remain undisclosed as the trial is still blinded. Additionally, Annovis is working on a new crystal form of its investigational drug, buntanetap, which may enhance its therapeutic potential.
Read more →ANVSAnnovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
Annovis Bio, Inc. announced its financial results for Q1 2023, reporting a net loss of $9.7 million, alongside updates on its clinical trials for Alzheimer’s and Parkinson’s diseases. The company showed strong enrollment in its Phase 3 study for Parkinson's Disease and announced plans to develop its lead candidate, buntanetap, with the FDA for all disease stages. Furthermore, they received EU approval to pursue clinical trials in additional countries and successfully raised approximately $8.7 million to fund ongoing research.
Read more →ANVSAnnovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
Annovis Bio has announced the issuance of a U.S. patent for its lead drug candidate, Buntanetap, focusing on its use for preventing and treating diseases related to metal dis-homeostasis. The patent ensures protection of Buntanetap's usage until early 2040 and covers its application in both healthy and sick individuals. The drug aims to restore heavy metal balance and has shown potential in treating neurodegenerative diseases while demonstrating safety and efficacy in previous clinical trials.
Read more →ANVS▼ -21.5%on this news
ANNOVIS BIO ANNOUNCES FOURTH QUARTER and full year 2022 financial
Annovis Bio, Inc. announced its fourth quarter and full year financial results for 2022, highlighting continued growth in clinical trial enrollment and the expansion of its intellectual property estate for its lead drug candidate, buntanetap. The company reported a net loss of $25.3 million for 2022, an increase compared to the prior year. Upcoming milestones include a blinded interim analysis of a Phase 2/3 Alzheimer's study expected in Fall 2023, positioning Annovis for an exciting year ahead driven by its clinical advancements.
Read more →ANVSAttacks Neurodegeneration, Alzheimer's and Parkinson's Diseases by Improving the Information Highway of the Nerve Cell February 2023 Symbol: ANVS (NYSE) - People Focused, Purpose Driven, Passion Powered - FORWARD-LOOKING
Annovis Bio has made strides in developing Buntanetap, a treatment targeting neurodegeneration associated with Alzheimer's and Parkinson's diseases. Phase 2a clinical trials have shown positive results, indicating improvements in cognitive and motor functions among patients. The mechanism of action involves enhancing axonal transport and reducing levels of neurotoxic proteins. As part of their ongoing research, Annovis is gearing up for further clinical trials in early and moderate Alzheimer's patients that could bring this therapeutic approach closer to market.
Read more →ANVSAttacks Neurodegeneration, Alzheimer's and Parkinson's Diseases by Improving the Information Highway of the Nerve Cell January 2023 Symbol: ANVS (NYSE) - People Focused, Purpose Driven, Passion Powered - FORWARD - LOOKIN
Annovis Bio is advancing its innovative treatment, Buntanetap, aimed at addressing neurodegenerative diseases like Alzheimer's and Parkinson's. Recent Phase 2a clinical trials have shown positive results, indicating improvements in cognitive and motor functions in affected patients. The company has launched a Phase 3 clinical study for early Parkinson's patients, reaffirming its commitment to further develop therapies for these conditions. Despite the promising data, the ongoing trial phase illustrates the challenges associated with bringing new drugs to market in the complex field of neurology.
Read more →ANVSAnnovis Bio Appoints Henry Hagopian III as Chief Financial Officer BERWYN, PA.
Annovis Bio Appoints Henry Hagopian III as Chief BERWYN, PA., Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian II
Read more →ANVSAnnovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update Berwyn, Pennsylvania
Bio Announces Second Quarter 2022 Results and Provides Corporate Update Pennsylvania-August 8, 2022 - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced second quarter financ
Read more →ANVS▲ +14.1%on this news
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update Berwyn, Pennsylvania
Bio Announces First Quarter 2022 Results and Provides Corporate Update Pennsylvania - May 4, 2022 - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financia
Read more →ANVSAnnovis Bio Announces Transfer of Listing to the New York Stock Exchange Trading to begin
Annovis Bio Announces Transfer of Listing to the New York Stock Exchange Trading to begin November 18, 2021 with current ticker "ANVS" BERWYN, PA., November 15, 2021 -- Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform compa
Read more →ANVS▼ -7.9%on this news
Annovis Bio Presented at the 14 th Clinical Trials on Alzheimer's Disease Conference With additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a study BERWYN, PA.
Bio Presented at the 14th Clinical Trials on Alzheimer's Disease Conference additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a study PA., November 12, 2021 -- Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-s
Read more →ANVSAnnovis Bio, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before October 18, 2021; click here to submit trade information LOS ANGELES, Oct. 08, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Annovis Bio, Inc
Read more →ANVS▼ -13.2%on this newsshared move
Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients Annovis Bio to Request Meeting wi
Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients Request Meeting with FDA on Next Steps in Clinical Development Call to be Hosted Tuesday
Read more →ANVS▼ -8.1%on this news
Frequently Asked Questions Annovis Bio Phase 2a Data Results 1. What interim results from the Phase 2a study of ANVS401 were recently announced by Annovis Bio? Why did some people believe the company's recent interim dat
Frequently Asked Questions Annovis Bio Phase 2a Data Results Answer: On July 28, we announced interim results among both Alzheimer's disease (AD) and Parkinson's disease (PD) patients from Phase 2a clinical trials of our lead compound, ANVS401 (Posiphen). The results were po
Read more →ANVSAnnovis Bio, Inc. Investors: Company Investigated by the Portnoy Law Firm
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Inve
Read more →ANVS▼ -9.2%on this newsshared move
ANNOVIS BIO INVESTIGATION: Block & Leviton Investigates Annovis For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Annovis Bio, Inc. (NYSE: ANVS) for potential securities law violations. Investors who have lost money in their Annovis investment should contact the firm to learn more about how they might recover those lo
Read more →ANVS▼ -60.3%on this newsshared move
AAIC Panel July 28, 2021 Symbol: ANVS (NYSE American)
AAIC Panel July 28, 2021 Symbol: ANVS (NYSE American) NEUROTOXIC PROTEINS IMPAIR AXONAL TRANSPORT AND CAUSE A TOXIC CASCADE Posiphen IMPROVES AXONAL TRANSPORT AND IMPEDES THE TOXIC CASCADE IMPAIRED AXONAL TRANSPORT SLOWER SYNAPTIC TRANSMISSION INFLAMMATION DEATH OF NERVE CELLS L
Read more →ANVSAnnovis Bio, Inc. Announces Proposed Public Offering of Common Stock Berwyn, PA
Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock Berwyn, PA - May 21, 2021 - Annovis Bio, Inc. (NASDAQ: ANVS) ("Annovis" or the "Company") a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurod
Read more →ANVSAnnovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman BERWYN, PA.
Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee Chairman BERWYN, PA. - April 15, 2021 - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodege
Read more →ANVSAttacks Alzheimer's Disease and Neurodegeneration by Improving the Information Highway of the Nerve Cell Axonal Transport March 2021 Symbol: ANVS (NYSE American) FORWARD - LOOKING STATEMENTS Statements in this presentati
Attacks Alzheimer's Disease and Neurodegeneration by Improving the Information Highway of the Nerve Cell Axonal Transport March 2021 Symbol: ANVS (NYSE American) FORWARD - LOOKING STATEMENTS Statements in this presentation contain "forward - looking statements" that are subject
Read more →ANVSAnnovis Bio, Inc. to present at the Q1 Virtual Investor Summit
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual Investor Summit. Event Q1 Investor Summit Date March 23-25th, 2021 Presentation M
Read more →ANVSAnnovis Bio to Present at the BIO CEO & Investor Digital Conference
BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder
Read more →ANVSAnnovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Macce
Read more →ANVSAnnovis Bio Showcases its Unique Approach to Alzheimer’s at the New York Academy of Sciences
BERWYN, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., pre
Read more →ANVSAnnovis Bio to Present at Benzinga Global Small Cap Conference on December 8, 2020
BERWYN, Pa., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., wil
Read more →ANVSAnnovis Bio to Present at the New York Academy of Sciences’ Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference
BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., wil
Read more →ANVSAnnovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium
BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and
Read more →ANVSAnnovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog coho
Read more →ANVSAnnovis Bio CEO to Present at Meridian Clinical Trials Summit
BERWYN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its Founder and CEO, Maria Maccecchini
Read more →ANVSAnnovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease after COVID-Related Delay
BERWYN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced it resumed treatment of patients in it
Read more →ANVSAnnovis Bio CEO Receives 2020 Smart Business Dealmaker Award
BERWYN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its Founder and Chief Executive Office
Read more →ANVSAnnovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair
BERWYN, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its Founder and Chief Executive Office
Read more →ANVSAnnovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its business highlights for the third
Read more →ANVSAnnovis Bio to Present at the 2020 BIO Investor Forum
BERWYN, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder
Read more →ANVSAnnovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
Manuscript Published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association Study adds further validation that Annovis’ lead compound is the only drug to improve axonal transport, the information highway of the nerve cell BERWYN, Pa., Sept. 29, 2020 (GLOBE NEWSWI
Read more →ANVSAnnovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial
BERWYN, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced dosing of the first three patients in
Read more →ANVSAnnovis Bio Actively Recruiting Patients for its Phase 2a Trials in Alzheimer’s and Parkinson’s Diseases
BERWYN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, is pleased to announce it has restarted patient recrui
Read more →ANVSAnnovis Bio CEO Appears on Executive Leaders Radio Program
BERWYN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., wil
Read more →ANVSAnnovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, is pleased to announce its CEO Maria Maccecchini, Ph.D
Read more →ANVSAnnovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, reported that it has received Central Institutional Re
Read more →ANVSAnnovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced it successfully completed the rat coho
Read more →ANVSAnnovis Bio to Present at the June 2020 Virtual Summer Investor Summit BERWYN, PA.
Bio to Present at the June 2020 Virtual Summer Investor Summit BERWYN, PA. - June 9, 2020 - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today
Read more →ANVSAnnovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
BERWYN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced the European Patent Office (EPO) grant
Read more →ANVSAnnovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
BERWYN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, will hold its 2020 Annual Meeting of Stockholders in
Read more →ANVSAnnovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19
BERWYN, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today that it filed a patent application with
Read more →ANVSAnnovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients
BERWYN, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today that the protocol for its Phase 2 cli
Read more →ANVSAnnovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
BERWYN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, published data from its two double-blind, placebo controlled an
Read more →ANVSAnnovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
BERWYN, Pa., April 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today its CEO Maria Maccecchini, Ph.D. will share ins
Read more →ANVSAnnovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
BERWYN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other neurodegenerative diseases, was awarded a $1.7 million grant from the National Institutes of Heal
Read more →ANVSAnnovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, was issued a patent (US 10,383,851) in August 2019 for a method of treating Park
Read more →ANVSAnnovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced today that the Data Safety Monitoring Board has reviewed the safety da
Read more →ANVSAnnovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BERWYN, Pa., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE American: ANVS), a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases, today announced the closing of its initial public offering of 2,000,000 shares
Read more →ANVSAnnovis Bio Announces Pricing of Initial Public Offering
BERWYN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases today announced the pricing of its initial public offering of 2,000,000 shares of its common stock at
Read more →ANVSAnnovis Appoints Jeffrey McGroarty Chief Financial Officer
BERWYN, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced that Jeffrey McGroarty has been appointed the Company’s Chi
Read more →Competitive Position
How ANVS ranks across every disease it competes inCompetitive Position is a premium feature
See how ANVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial